Drug Repurposing Market Size Projected To Increase From $40.95 Billion To $58.33 Billion During The Forecast Period
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Drug Repurposing Market Growth From $40.95 Billion In 2026 To $58.33 Billion By 2030 At A CAGR Of 9.2%
The drug repurposing market has experienced robust expansion over recent years. Its value is projected to rise from $37.38 billion in 2025 to $40.95 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.6%. This historical growth has been fueled by several factors, including the substantial expenses and time required for conventional drug discovery, a growing volume of unsuccessful drug candidates, a higher incidence of chronic and rare conditions, scarce therapeutic alternatives for new diseases, and the early integration of computational approaches for drug repositioning.
The market for drug repurposing is projected to experience robust expansion over the coming years, reaching an estimated $58.33 billion by 2030, representing a compound annual growth rate (CAGR) of 9.2%. This forecasted growth is driven by several key factors, including the integration of artificial intelligence and machine learning into repurposing efforts, heightened investment in biotechnology and pharmaceutical research, the broadening capabilities of contract research organizations (CROs), increased demand for cost-effective treatment options, and favorable regulatory frameworks for approving repurposed medications. Prominent trends shaping this period involve a stronger emphasis on phenotypic and target-based screening methods, a rising preference for structure-based drug repositioning, advancements in identifying off-target activities, the expansion of repurposing applications to rare and infectious diseases, and the acceleration of development timelines by leveraging existing compounds.
Download A Free Sample Report For Comprehensive Market Insights:
Drug Repurposing Market Industry Drivers: What Is Driving Revenue Growth?
The increasing occurrence of neurodegenerative conditions is set to boost the expansion of the drug repurposing market in the coming years. Neurodegenerative diseases encompass a category of conditions marked by the gradual deterioration and eventual death of neurons, leading to a loss of structure or function. A rising number of cases, including Alzheimer’s dementia, stems from extended life expectancy, as aging stands out as the primary risk factor responsible for the progressive decline in neuronal activity over time. Drug repurposing aids in managing these diseases by leveraging existing medications with well-established safety records, which can be repurposed to address specific disease mechanisms, thereby speeding up the development of viable therapies. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts predicting this number will rise to 13.8 million by 2060. Thus, the growing prevalence of neurodegenerative diseases is fueling the growth of the drug repurposing market.
Drug Repurposing Market Segment Landscape And Growth Potential
The drug repurposing market covered in this report is segmented –
1) By Type: Disease-Centric, Target-Centric, Drug-Centric
2) By Drug Molecules: Biologics, Small Molecule
3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders
4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular
5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations
Subsegments:
1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing
2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting
3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing
Drug Repurposing Market Growth Trends: What Is Influencing The Future Outlook?
Key players in the drug repurposing market are increasingly investing in the development of sophisticated technologies, such as artificial intelligence-driven drug-protein interaction models, to expedite the discovery of new therapeutic applications for existing medications. This approach applies machine learning and AI techniques to forecast how drugs bind to proteins throughout the human proteome, utilizing extensive datasets to boost both predictive precision and reliability. A notable example occurred in July 2025, when Cosmos Health Inc., a healthcare firm headquartered in the United States, launched Cloudscreen 2.0, an advanced AI system tailored for drug repurposing. This next-generation tool can process datasets more than 100 times larger than its predecessor, facilitating thorough exploration of drug-protein interactions. By integrating mutagenesis information and capabilities for studying disordered proteins, the platform targets key diseases like cancer, obesity, and diabetes. Furthermore, the use of GPU-based cloud computing enables scalable data processing, positioning this platform as a pivotal advancement in speeding up research and development efforts for drug repurposing across a wide range of therapeutic fields.
Drug Repurposing Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.
Access The Complete Drug Repurposing Market Report:
Drug Repurposing Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
